

## GFAP

**Cat.No. 173 111; Monoclonal mouse antibody, 100 µg purified IgM (lyophilized)**

### Data Sheet

Reconstitution/ Storage	100 µg purified IgM, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H <sub>2</sub> O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C until use.
Applications	<b>WB:</b> not recommended <b>IP:</b> yes <b>ICC:</b> 1 : 500 <b>IHC:</b> 1 : 500 <b>IHC-P/FFPE:</b> not tested yet
Clone	64F6
Subtype	IgM (κ light chain)
Immunogen	Recombinant protein corresponding to AA 1 to 432 from human GFAP (UniProt Id: P14136)
Epitop	Epitop: AA 1 to 432 from human GFAP (UniProt Id: P14136)
Reactivity	Reacts with: rat (P47819), mouse (P03995), human (P14136). No signal: zebrafish. Other species not tested yet.
Specificity	Specific for GFAP.
matching control	173-0P

**TO BE USED IN VITRO / FOR RESEARCH ONLY**  
**NOT TOXIC, NOT HAZARDOUS, NOT INFECTIOUS, NOT CONTAGIOUS**

Glial fibrillary acidic protein **GFAP** is a glial-specific member of the intermediate filament protein family. This group comprises celltype-specific filamentous proteins with similar structure and function as scaffold for cytoskeleton assembly and maintenance.

Frequently, neural stem cells also express GFAP. In addition many types of brain tumors, probably derived from astrocytic cells, heavily express GFAP. This protein is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and others.

Point-mutations in the GFAP gene have been correlated to Alexander disease a fatal leukoencephalopathy that leads to the dysmyelination or demyelination of the central nervous system.

### Selected General References

Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage.  
Triolo D, Dina G, Lorenzetti I, Malaguti M, Morana P, Del Carro U, Comi G, Messing A, Quattrini A, Previtali SC  
Journal of cell science (2006) 119(Pt 19): 3981-93.

Asymptomatic hereditary Alexander's disease caused by a novel mutation in GFAP.  
Shiihara T, Sawaishi Y, Adachi M, Kato M, Hayasaka K  
Journal of the neurological sciences (2004) 225(1-2): 125-7.

Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000).  
Eng LF, Ghirnikar RS, Lee YL  
Neurochemical research (2000) 25(9-10): 1439-51.

GFAP-positive and myelin marker-positive glia in normal and pathologic environments.  
Dyer CA, Kendler A, Jean-Guillaume D, Awatramani R, Lee A, Mason LM, Kamholz J  
Journal of neuroscience research (2000) 60(3): 412-26.

Expression of GFAP immunoreactivity during development of long fiber tracts in the rat CNS.  
Valentino KL, Jones EG, Kane SA  
Brain research (1983) 285(3): 317-36.

Glial fibrillary acidic protein (GFAP): purification from human fibrillary astrocytoma, development and validation of a radioimmunoassay for GFAP-like immunoactivity.  
Palfreyman JW, Thomas DG, Ratcliffe JG, Graham DI  
Journal of the neurological sciences (1979) 41(1): 101-13.

Determination of glial fibrillary acidic protein (GFAP) in human brain tumors.  
Jacque CM, Vinner C, Kujas M, Raoul M, Racadot J, Baumann NA  
Journal of the neurological sciences (1978) 35(1): 147-55.